# Antibody-drug conjugate market development

> Live situation record from CLSTR: https://clstr.news/situations/antibody-drug-conjugate-market-development
> Updated: 2026-10-02T13:16:27.000Z. Sources: 6. Developments: 3.

The antibody-drug conjugate (ADC) sector is experiencing significant investment and technological evolution. Individual companies are expanding their capabilities through strategic funding and rights acquisitions, such as Cohance Lifesciences’ $18 million investment in NJ Bio and Aruka Bio, and Medicus Pharma Ltd.’s $27 million agreement with Pfizer Inc. for the compound CD228V.

The market is projected to grow from $14.23 billion in 2025 to $453.9 billion by 2035, maintaining a compound annual growth rate of 12.30%. Recent developments include the 2025 US FDA approvals of Daiichi Sankyo’s DATROWAY for breast cancer and non-small cell lung cancer treatments. 

Technological shifts focus on next-generation platforms prioritizing improved drug delivery, linker stability, and higher drug-to-antibody ratios. This includes advancements in antibody discovery, where platforms like Converge Bio utilize target-aware design and multiparameter optimization to balance binding affinity with developability. 

Emerging trends include the development of bispecific ADCs. For example, NEOK Bio is developing dual-target therapies for ROR1/B7-H3 and EGFR/MUC1, with Phase 1 clinical trials expected to begin in mid-2026. Successful development continues to rely on specialized bioconjugation expertise to manage the interdependence of the antibody, the linker, and the cytotoxic payload.

## Timeline

### 2026-10-02: Antibody discovery and ADC development drive oncology innovation

Advancements in antibody discovery platforms and the growing ADC market are driving precision oncology, with the ADC sector projected to reach $36 billion by 2034.

2 sources. https://clstr.news/cluster/antibody-discovery-and-adc-development-drive-oncology-innovation

### 2026-09-30: Antibody-drug conjugate market projected to reach $453.9 billion by 2035

The antibody-drug conjugate (ADC) market is forecast to reach $453.9 billion by 2035, driven by advancements in precision medicine, new FDA approvals, and the development of bispecific ADC technologies.

2 sources. https://clstr.news/cluster/antibody-drug-conjugate-market-projected-to-reach-4539-billion-by-2035

### 2026-09-04: Pharmaceutical companies expand antibody-drug conjugate portfolios

Cohance Lifesciences is investing $18 million to expand its cancer treatment portfolio, while Medicus Pharma has acquired worldwide rights to a Pfizer antibody-drug conjugate for $27 million.

2 sources. https://clstr.news/cluster/pharmaceutical-companies-expand-antibody-drug-conjugate-portfolios

---
Cite as: Antibody-drug conjugate market development. CLSTR, https://clstr.news/situations/antibody-drug-conjugate-market-development